Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OptimizeRx (OPRX) Accumulated Expenses: 2010-2024

Historic Accumulated Expenses for OptimizeRx (OPRX) over the last 15 years, with FY2024 value amounting to $8.5 million.

  • OptimizeRx's Accumulated Expenses rose 8351.63% to $10.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.2 million, marking a year-over-year increase of 8351.63%. This contributed to the annual value of $8.5 million for FY2024, which is 1012.2% up from last year.
  • OptimizeRx's Accumulated Expenses amounted to $8.5 million in FY2024, which was up 1012.2% from $7.7 million recorded in FY2023.
  • OptimizeRx's 5-year Accumulated Expenses high stood at $8.5 million for FY2024, and its period low was $2.4 million during FY2020.
  • Over the past 5 years, OptimizeRx's median Accumulated Expenses value was $2.9 million (recorded in 2021), while the average stood at $4.8 million.
  • In the last 5 years, OptimizeRx's Accumulated Expenses crashed by 1038.95% in 2022 and then soared by 19624.26% in 2023.
  • Annual analysis of 5 years shows OptimizeRx's Accumulated Expenses stood at $2.4 million in 2020, then rose by 19.93% to $2.9 million in 2021, then fell by 10.39% to $2.6 million in 2022, then skyrocketed by 196.24% to $7.7 million in 2023, then increased by 10.12% to $8.5 million in 2024.
  • Its Accumulated Expenses was $8.5 million in FY2024, compared to $7.7 million in FY2023 and $2.6 million in FY2022.